Peter Hofland | ADC Review

Home Authors Posts by Peter Hofland

508 POSTS 0 COMMENTS

https://sunvalleycommunication.com

Peter Hofland, Ph.D is the Executive Editor of ADC Review, Journal of Antibody-drug Conjugates, a comprehensive digital platform and peer reviewed publication focusing on news and information about innovative therapies such as Antibody-drug Conjugates (ADCs). Hofland contributes articles on the advances in ADCs - from initial discovery to approved drug. He is also a contributor to Onco'Zine and The Onco'Zine Brief. For more information about Hofland, check his ORCID profile here.

Sacituzumab Govitecan Increases PFS for Patients With Most Common Type of...

Featured Image Courtesy: Byondis Biopharmaceuticals (previously Synthon Biopharmaceuticals, Nijmegen, The Netherlands.

Byondis and Medac Sign Collaboration and Supply Agreements for Trastuzumab Duocarmazine

Withdrawal of FDA’s Accelerate Approved Therapeutic Agents may harm Patients

José Baselga, a Leading Cancer Researcher, Dies at 61

Astellas Pharma. Exhibition booth during the 2019 annual meeting of the American Society of Medical Oncology (ASCO).

Astellas and Seagen Submit sBLA for Enfortumab Vedotin in Locally Advanced...

Research associate at Genmab, Cell culturing. Photo courtesy: 2020 Genmab/Tuala Hjarnø and Torkil Stavdal

Biologics License Application for Tisotumab Vedotin Submitted to the U.S. Food...

First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients...

Speakers and attendees during Global Capacity Building Showcase at the American Society of Hematology 61th Annual Meeting at the Orange County Convention Center on Sunday December 8, 2019. Photo Courtesy 2019 © ASH/Nick Agro

ASH 2020: Preclinical Models Identify CD74 as Potential Target for the...

ASH 2020: ECHELON-1 and ECHELON-2 and other Results with Brentuximab Vedotin

ASH 2020: Positive Interim Phase I Study Results of TRPH-222 in...

12 3...51 Page 1 of 51